A research study about factors that might increase the chance of getting breast and ovarian cancers. Eligible: female 18-80 yr old; diagnosed with breast cancer under age 50; diagnosed with ovarian cancer at any age; strong family history of breast and/or ovarian cancer.
Marcela Mazo Canola, MD, helps us understand breast cancer signs, symptoms and risks.
Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.
UT Health San Antonio’s Mays Cancer Center is hosting a Grand Rounds Oct. 15 — Global Lobular Breast Cancer Awareness Day — to spotlight new approaches to diagnosis and treatment of invasive lobular carcinoma, a common but often overlooked form of breast cancer.
BRCA1 and BRCA2 are genes that help protect the body by fixing damaged DNA and keeping cells healthy. When these genes have changes, or mutations, they don’t work the way they should. This can raise the risk of certain cancers, like breast, ovarian, prostate and pancreatic cancer. These inherited mutations affect about 1 in every 200 to 300 people — over a million in the U.S. alone.
Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast cancer patients with hormone receptor-positive tumors, which represent 75% of all breast cancer diagnoses. Long-term use of EHT reduces cancer recurrence rates and cuts the risk of death nearly in half during the second decade after diagnosis, research shows. Despite the proven benefits, about 33% of women who are prescribed EHT do not take their medication as prescribed (less than 80% take their daily dosage) and are thus at higher risk of recurrence and death. This educational randomized controlled study will develop and pilot-test a bilingual, culturally tailored, personalized, interactive mobile application (app) in combination with patient navigation to promote and improve adherence to endocrine hormonal therapy (EHT) among breast cancer patients.
Marcela Mazo Canola, MD, breast medical oncologist at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses how breast cancer has impacted the Hispanic/Latino population and the importance of breast cancer screenings. She also shares the signs of symptoms, along with the risk factors and what women can do to […]
This is a prospective, observational study designed to evaluate the clinical validity of Myriad Genetics’ MRD test in patients diagnosed with breast cancer. It is expected that enrollment will be split between the different breast cancer subtypes defined by immunohistochemistry (HR+/HER2-, HER2+ (HR+ and HR-), TNBC) and according to BINV-A of National Comprehensive Cancer Network guidelines with ER+ status used here as >10% of nuclei staining.
Close
